Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Ferry A. Eskens"'
Autor:
Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, Vincent van der Noort, Henk M.W. Verheul, John B.A.G. Haanen, Astrid A.M. van der Veldt, Ferry A.L.M. Eskens, Maureen J.B. Aarts, Carla M.L. van Herpen, Mathilde Jalving, Jourik A. Gietema, Lot A. Devriese, Mariette Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F. Smit, Haiko J. Bloemendal
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100875- (2024)
Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD
Externí odkaz:
https://doaj.org/article/fc99db69ccab44d8b32b3ad075d188c3
Autor:
Sonja Levy, Wieke H.M. Verbeek, Ferry A.L.M. Eskens, José G. van den Berg, Derk Jan A. de Groot, Monique E. van Leerdam, Margot E.T. Tesselaar
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Extrapulmonary neuroendocrine carcinoma (EP-NEC) are an aggressive subgroup of neuroendocrine neoplasms (NEN). Advanced EP-NEC is generally treated with platinum-based cytotoxic regimens, but progressive disease occurs rapidly, resulting
Externí odkaz:
https://doaj.org/article/69ebeb322ba14b3493c684e1c3016d90
Autor:
Hendrik-Tobias Arkenau, Marta Gil-Martin, Fiona Thistlethwaite, Aung Naing, Karen A. Autio, Patrick A. Ott, Johanna Bendell, Patricia LoRusso, Valentina Boni, Alexander Spira, Javier Garcia-Corbacho, Mark Stroh, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Manreet Randhawa, Greg Durm, Alison L. Hannah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Probody® therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing ‘off-tumor’ toxicity. We report
Externí odkaz:
https://doaj.org/article/e9995b5c481945709e7709fd5db97be9
Autor:
Mustafa Suker, Joost J. Nuyttens, Ferry A.L.M. Eskens, Brigitte C.M. Haberkorn, Peter-Paul L.O. Coene, Erwin van der Harst, Bert A. Bonsing, Alexander L. Vahrmeijer, J.Sven D. Mieog, Rutger Jan Swijnenburg, Daphne Roos, B.Groot. Koerkamp, Casper H.J. van Eijck
Publikováno v:
EClinicalMedicine, Vol 17, Iss , Pp - (2019)
Background: We conducted a multicentre phase II trial to investigate feasibility and antitumor activity of sequential FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC), (LAPC-1 trial). Met
Externí odkaz:
https://doaj.org/article/a418d643cf42499e991cf16f2da3aa38
Autor:
Jan H.M. Schellens, Tim Demuth, Kati Maharry, Eugene Tan, Savina Jaeger, Arkendu Chatterjee, Emin Avsar, Zev A. Wainberg, Heinz-Josef Lenz, Rona Yaeger, Sunil Sharma, Ferry A.L.M. Eskens, Jason E. Faris, Martijn P. Lolkema, Yasuhide Yamada, Jean-Pierre Delord, Takayuki Yoshino, Martin Schuler, Anna Spreafico, Johanna C. Bendell, Elena Elez, Josep Tabernero, Robin M.J.M. van Geel
Table S1. Pharmacokinetic parameters of encorafenib and alpelisib in patients at steady state (cycle 2 day 1). Table S2. Criteria for defining dose-limited toxicities. Supplementary Figure 1. Radiological images of response for a patient treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1341dd8cec12a541df23cf9cbed4ad9b
https://doi.org/10.1158/2159-8290.22532039
https://doi.org/10.1158/2159-8290.22532039
Autor:
Peter de Bruijn, Sander Bins, Ferry A.L.M. Eskens, Femke M. de Man, Ron H.J. Mathijssen, Niels Heersche, Esther Oomen-de Hoop, Leni van Doorn, Ivo Bijl, Ate van der Gaast
Publikováno v:
Clinical Pharmacology and Therapeutics, 111(2), 455-460. Wiley-Blackwell
Retrospective data suggest that gastric acid reduction by proton pump inhibitors (PPIs) impairs the dissolution and subsequent absorption of capecitabine, and thus potentially reduces the capecitabine exposure. Therefore, we examined prospectively th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::814759c4ce80aa423634215ecc3cfb08
https://doi.org/10.1002/cpt.2444
https://doi.org/10.1002/cpt.2444
Autor:
Ferry ALM Eskens, Jaap Verweij, Johann Sebastian De Bono, Leon Hooftman, Martin Toal, Michelle Dawn Garrett, Florence Raynaud, Adam Stewart, Matthew Tall, Phillip Debnam, Rebecca Kristeleit, Dionysis Papadatos-Pastos, Leni van Doorn, Udai Banerji
PDF file - 42K, CHR-3996
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f2832c4ab895bcac07ce8525bec35d6
https://doi.org/10.1158/1078-0432.22445493.v1
https://doi.org/10.1158/1078-0432.22445493.v1
Autor:
Stefan Sleijfer, Elisabeth G.E. de Vries, Walter J. Loos, Ferry A.L.M. Eskens, Renée Miceli, Norma Lynn Fox, Jourik A. Gietema, Corina N.A.M. Oldenhuis, Jaap Verweij, Constantijne H. Mom
Supplementary Data from Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc8175e10fc63c1c449e22f11fd3876
https://doi.org/10.1158/1078-0432.22440649
https://doi.org/10.1158/1078-0432.22440649
Autor:
Judith V.M.G. Bovée, Karoly Szuhai, Geert J.L.H. van Leenders, Ferry A.L.M. Eskens, Hans Gelderblom, Stefan Sleijfer, David G.P. van IJzendoorn
Supplementary table 1 Primers sequences used for Real-Time qPCR. Supplementary table 2 ShRNA used for inhibition of the receptors, for each receptor the most effective shRNA was selected as tested with Real-Time qPCR. Supplementary table 3 Sequence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14386f00029181604781520ebdd88e28
https://doi.org/10.1158/1078-0432.22470197.v1
https://doi.org/10.1158/1078-0432.22470197.v1
Autor:
Andrew Krivoshik, Anne Keating, Howard A. Ball, Chip Van Sant, Jihong Chen, Sandra Vossen, Carolyn Sasse, Ferry A.L.M. Eskens, John Bridgewater, Igor Kiss, Al B. Benson
Patient Disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01105bff1777c1397f541eae29d56c27
https://doi.org/10.1158/1078-0432.22465994.v1
https://doi.org/10.1158/1078-0432.22465994.v1